News | March 06, 2024
Bayer aims to enhance performance and regain strategic flexibility by 2026
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
The ninth acquisition since 2018
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated
